Evaluating ALN-BCAT for liver cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and tolerability of ALN-BCAT, both alone and in combination with pembrolizumab, in patients with advanced or metastatic hepatocellular carcinoma (HCC). The study consists of a dose escalation phase to determine the recommended doses for further evaluation and a dose expansion phase to investigate the antitumor activity of the treatment. Patients will be monitored for safety and efficacy throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has HCC confirmed histologically or cytologically, or, for patients with liver cirrhosis, clinically by the American Association for the Study of Liver Diseases (AASLD) criteria
* Has had at least one line of systemic therapy for unresectable advanced or metastatic disease
* Has at least one wingless-related integration site (WNT)-pathway activating mutation
* Child-Pugh class A or B7

Exclusion Criteria:

* Has fibrolamellar HCC, sarcomatoid HCC, or mixed cholangio-HCC tumors
* Has symptomatic extrahepatic disease
* Has received anti-cancer therapy or investigational drugs ≤3 weeks prior to the first dose of study drug

Note: other protocol defined inclusion / exclusion criteria apply

Where it's running

• Clinical Trial Site
  Phoenix, Arizona, United States Recruiting
• Clinical Trial Site
  La Jolla, California, United States Recruiting
• Clinical Trial Site
  Los Angeles, California, United States Recruiting
• Clinical Trial Site
  Jacksonville, Florida, United States Recruiting
• Clinical Trial Site
  Atlanta, Georgia, United States Recruiting
• Clinical Trial Site
  Chicago, Illinois, United States Recruiting

Study contacts

• Study coordinator: Alnylam Clinical Trial Information Line
• Email: clinicaltrials@alnylam.com
• Phone: 1-877-ALNYLAM

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Tumor Treating Fields with Cabozantinib or Pembrolizumab and Nab-Paclitaxel for Advanced Solid Tumors

  This study is testing a new treatment that combines tumor treating fields with two different cancer drugs to see if it helps people with advanced solid tumors in the abdomen or chest.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT05092373

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery

  This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.

  Recruiting at 60 sites Phase 1/2 Pfizer · Irvine, California and 59 other locations · NCT07227012

• Celecoxib with durvalumab and tremelimumab for advanced liver cancer

  This phase II trial tests whether adding the oral drug celecoxib to the immunotherapy drugs durvalumab and tremelimumab helps people with advanced or metastatic liver cancer.

  Recruiting at 3 sites Phase 2 Emory University · Atlanta, Georgia and 3 other locations · NCT07174570

• Sapanisertib plus cabozantinib for metastatic liver cancer with beta-catenin changes

  This trial tests whether adding sapanisertib to cabozantinib helps people with metastatic liver cancer that has a beta-catenin gene change.

  Recruiting at 4 sites Phase 1/2 National Cancer Institute (NCI) · Irvine, California and 3 other locations · NCT06811116

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.